Digest Network Come funziona
Network
/
Società
Sh
Non verificato

Shorla Oncology

Di cosa scriviamo

FarmaceuticaIgiene alimentareIndustriaOncologiaSalute

6 comunicati stampa

Guarda tutti i comunicati
15/07/2025
Industria
Igiene alimentare
Sanità
Salute
Farmaceutica
Oncologia
Scienza
Shorla Oncology Announces FDA Orphan Drug Designation for SH-110 to Treat Rare Brain Cancer Using Oral Liquid
Fonte
Shorla Oncology
Emittente
Business Wire
1.00
0
29/04/2025
Shorla Oncology Announces FDA Approval of TEPYLUTE® 100mg, First and Only Ready-to-Dilute Multi-Dose Vial of Thiotepa to Treat Breast and Ovarian Cancer and Commercial Launch of TEPYLUTE 15mg and 100mg Vials in the U.S.
Fonte
Shorla Oncology
Emittente
Business Wire
1.00
0
04/03/2025
Shorla Oncology Announces Expansion of U.S. Commercial Footprint with Launch of Dedicated Sales Force and Market Access Teams
Fonte
Shorla Oncology
Emittente
Business Wire
1.00
0
25/11/2024
Multimedialità
Industria
Igiene alimentare
Farmaceutica
Salute
Oncologia
Shorla Oncology Announces FDA Approval of IMKELDI (imatinib) Oral Solution, an Oral Liquid for the Treatment of Certain Forms of Leukemia and Other Cancers
Fonte
Shorla Oncology
Emittente
Business Wire
1.00
0
29/10/2024
Shorla Oncology Announces U.S. Food and Drug Administration (FDA) Expanded Approval of JYLAMVO™ (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications
Fonte
Shorla Oncology
Emittente
Business Wire
1.00
0
28/06/2024
Industria
Igiene alimentare
Sanità
Salute
Farmaceutica
Oncologia
Scienza
Shorla Oncology Announces FDA Approval for TEPYLUTE, A Novel Formulation to Treat Breast and Ovarian Cancer
Fonte
Shorla Oncology
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0